ADAM9 Protein, Cynomolgus, Recombinant (His)

A disintegrin and metalloproteinase 9 (ADAM9) is a member of the transmembrane ADAM family. It is expressed in different types of solid cancer and promotes tumor invasiveness. ADAM9 may be a prognostic marker for vestibular schwannomas (VS), and ADAM9 inhibition might have the potential as a systemic approach for the treatment of VS.

Pack Size	Availability	Price/USD
100 μg	5 days	$ 487.00
500 μg	5 days	$ 1,950.00
1 mg	5 days	$ 3,250.00

Pack Size

Availability

Price/USD

Quantity

100 μg

5 days

$ 487.00

500 μg

5 days

$ 1,950.00

1 mg

5 days

$ 3,250.00

Description

Species	Cynomolgus
Expression System	HEK293
Tag	C-His
Accession Number	A0A2K5X4X8
Synonyms	Adam9, CORD9, mKIAA0021, Meltrin-γ, Meltrin-gamma, ADAM 9, Mltng, MCMP, AU020942, Mdc9, Kiaa0021
Construction	Recombinant Cynomolgus ADAM9 Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Ala29-Gly698.[Accession \|A0A2K5X4X8]
Protein Purity	> 90% as determined by Tris-Bis PAGE; > 90% as determined by HPLC
Molecular Weight	The protein has a predicted MW of 74.90 kDa. The protein migrates to 65-115 kDa based on Tris-Bis PAGE result.

Endotoxin	Less than 1EU per μg by the LAL method.
Formulation	Supplied as 0.22μm filtered solution in PBS (pH 7.4).
Stability & Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Shipping	In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Research Background	A disintegrin and metalloproteinase 9 (ADAM9) is a member of the transmembrane ADAM family. It is expressed in different types of solid cancer and promotes tumor invasiveness. ADAM9 may be a prognostic marker for vestibular schwannomas (VS), and ADAM9 inhibition might have the potential as a systemic approach for the treatment of VS.